Skip to main content
Evidence Snapshot

Adenosine receptor A2a

CHEMBL251 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:14Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL251
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Adenosine receptor A2a as ChEMBL target CHEMBL251, mapped to UniProt P29274. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Adenosine receptor A2a
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL251
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P29274
Adenosine receptor A2a
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Adenosine receptor A2a matters

As of 2026-09-14

Adenosine receptor A2a is reviewed as Adenosine receptor A2a (UniProt P29274); Adenosine receptor A2a shows approved-linked disease relevance led by Parkinson disease. 5 more disease programs remain visible in the same review block.; 7 linked drugs keep this evidence frame grounded.; the current evidence base includes 45 approved drugs, 13409 compounds, and 1459 assays, with lead potency reaching pChEMBL 11.0.

Disease context
Parkinson disease

Adenosine receptor A2a shows approved-linked disease relevance led by Parkinson disease. 5 more disease programs remain visible in the same review block. 7 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include CIFORADENANT, ISTRADEFYLLINE, PBF-509.

Start review with Parkinson disease because it currently carries approved-linked support. Linked drugs include CIFORADENANT, ISTRADEFYLLINE, PBF-509, PRELADENANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 7 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 45 approved drugs, 13409 compounds, and 1459 assays for this target. The dominant activity type is KI. CHEMBL2419139 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL2419139 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
45 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Adenosine receptor A2a matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P29274, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Parkinson disease is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

13409
Total Compounds
1459
Total Assays
45
Approved Drugs
IC50: 2965.0, KI: 9010.0, EC50: 377.0, KD: 160.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL2419139
 11.0 Ki —
No preferred name
CHEMBL4167125
 11.0 IC50 —
No preferred name
CHEMBL1092271
 10.8 Ki —
No preferred name
CHEMBL2419146
 10.6 Ki —
No preferred name
CHEMBL2419147
 10.5 Ki —

Approved Drugs

Structure Compound First Approval
ISTRADEFYLLINE
CHEMBL431770
 2013
REGADENOSON ANHYDROUS
CHEMBL317052
 2008
SILDENAFIL
CHEMBL192
 1998
ADENOSINE
CHEMBL477
 1989
THEOPHYLLINE
CHEMBL1355736
 1976
TRIOXSALEN
CHEMBL1475
 1964
HEXACHLOROPHENE
CHEMBL496
 1949
BITHIONOL
CHEMBL290106
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:14Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL251